No Data
No Data
EVP, Chief Financial Officer Erick Lucera Sells 22,337 Shares of Editas Medicine Inc (EDIT)
Form 144 | Editas Medicine(EDIT.US) Officer Proposes to Sell 256.95K in Common Stocks
SEC FILLINGS DISCLOSED/ May 17, $Editas Medicine(EDIT.US)$ Officer Lucera Erick intends to sell 45,000 shares of its common stock on May 17, with a total market value of approximately $256.95K. Sou
Director Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (EDIT)
On May 13, 2024, Jessica Hopfield, Director at Editas Medicine Inc (NASDAQ:EDIT), purchased 45,000 shares of the company, as reported in the SEC Filing.
Editas Medicine(EDIT.US) Director Buys US$253.87K in Common Stock
$Editas Medicine(EDIT.US)$ Director Hopfield Jessica purchased 45,000 shares of common stock on May 13, 2024 at an average price of $5.6415 for a total value of $253.87K.Source: Announcement What is s
Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing
Jessica Hopfield, Director, on May 13, 2024, executed a purchase for 45,000 shares in Editas Medicine (EDIT) for $253,868.
Editas Medicine to Present Clinical Data From the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster
No Data